BRPI0514425A - inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos - Google Patents

inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos

Info

Publication number
BRPI0514425A
BRPI0514425A BRPI0514425-6A BRPI0514425A BRPI0514425A BR PI0514425 A BRPI0514425 A BR PI0514425A BR PI0514425 A BRPI0514425 A BR PI0514425A BR PI0514425 A BRPI0514425 A BR PI0514425A
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
compositions
treatments
same
Prior art date
Application number
BRPI0514425-6A
Other languages
English (en)
Inventor
Javier Gonzalez
Tanya Michelle Jewell
Hui Li
Angelica Linton
John Howard Tatlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0514425A publication Critical patent/BRPI0514425A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INIBIDORES DE RNA POLIMERASE DEPENDENTE DE RNA DO VìRUS DA HEPATITE C, E COMPOSIçõES E TRATAMENTOS USANDO OS MESMOS. A presente invenção fornece os compostos da fórmula (4), e seus sais farmaceuticamente aceitáveis e solvatos que são úteis como inibidores da enzima de polimerase do vírus da Hepatite C (HCV) e são também úteis para o tratamento de infecções de HCV em mamíferos infectados por HCV. A presente invenção também fornece composições farmacêuticas compreendendo as compostos da fórmula (4), seus sais farmaceuticamente aceitáveis e solvatos. Além disso, a presente invenção fornece compostos intermediários e métodos úteis na preparação dos compostos da fórmula (4).
BRPI0514425-6A 2004-08-18 2005-08-05 inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos BRPI0514425A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18
PCT/IB2005/002697 WO2006018725A1 (en) 2004-08-18 2005-08-05 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Publications (1)

Publication Number Publication Date
BRPI0514425A true BRPI0514425A (pt) 2008-06-10

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514425-6A BRPI0514425A (pt) 2004-08-18 2005-08-05 inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos

Country Status (42)

Country Link
US (3) US7151105B2 (pt)
EP (1) EP1781662B1 (pt)
JP (1) JP4372195B2 (pt)
KR (1) KR100851178B1 (pt)
CN (2) CN101538268B (pt)
AP (1) AP2313A (pt)
AR (1) AR050699A1 (pt)
AT (1) ATE506364T1 (pt)
AU (1) AU2005273619B2 (pt)
BR (1) BRPI0514425A (pt)
CA (1) CA2577525C (pt)
CR (2) CR8935A (pt)
CY (1) CY1111480T1 (pt)
DE (1) DE602005027580D1 (pt)
DK (1) DK1781662T3 (pt)
EA (1) EA012605B1 (pt)
EC (1) ECSP077264A (pt)
ES (1) ES2361845T3 (pt)
GE (2) GEP20094751B (pt)
GT (1) GT200500221A (pt)
HN (1) HN2005000449A (pt)
HR (1) HRP20110458T1 (pt)
IL (2) IL180933A (pt)
MA (1) MA28803B1 (pt)
MX (1) MX2007001527A (pt)
MY (1) MY146123A (pt)
NI (1) NI200700043A (pt)
NL (1) NL1029755C2 (pt)
NO (1) NO20071274L (pt)
NZ (1) NZ552874A (pt)
PE (1) PE20060677A1 (pt)
PL (1) PL1781662T3 (pt)
PT (1) PT1781662E (pt)
RS (1) RS51794B (pt)
SI (1) SI1781662T1 (pt)
SV (1) SV2007002202A (pt)
TN (1) TNSN07066A1 (pt)
TW (1) TWI376379B (pt)
UA (1) UA88909C2 (pt)
UY (1) UY29068A1 (pt)
WO (1) WO2006018725A1 (pt)
ZA (1) ZA200700779B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA88909C2 (ru) * 2004-08-18 2009-12-10 Пфайзер Инк. Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение
CN102336758A (zh) * 2005-08-24 2012-02-01 辉瑞有限公司 作为hcv聚合酶抑制剂的化合物及组合物
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びhcv感染の治療におけるその使用
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
SI2320905T1 (sl) 2008-08-11 2017-10-30 Glaxosmithkline Llc Corporation Service Company Novi adeninski derivati
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
AU2010333656B2 (en) * 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
EP2534149B1 (en) 2010-02-10 2014-10-15 GlaxoSmithKline LLC 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
DK2571854T3 (en) * 2010-05-20 2015-02-09 Bayer Ip Gmbh PROCESS FOR THE PREPARATION OF 1-alkyl-3-difluoromethyl-5-hydroxypyrazoles
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) * 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
KR102006518B1 (ko) 2012-05-14 2019-08-01 바이엘 크롭사이언스 악티엔게젤샤프트 1-알킬-3-플루오로알킬-1h-피라졸-4-카르복실산 클로라이드의 제조 방법
US9163027B2 (en) 2012-11-21 2015-10-20 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
US9932312B2 (en) 2013-01-17 2018-04-03 Bayer Cropscience Ag Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1H-pyrazole-4-carbaldehyde
ES2656012T3 (es) 2013-02-06 2018-02-22 Bayer Cropscience Aktiengesellschaft Derivados de pirazol sustituidos con halógeno como pesticidas
AU2014375265B2 (en) 2014-01-03 2018-11-01 Elanco Animal Health Gmbh Novel pyrazolyl-heteroarylamides as pesticides
DK3097081T3 (da) 2014-01-24 2018-01-29 Bayer Cropscience Ag Fremgangsmåde til fremstilling af 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carbaldehyder og 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carboxylater
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
JP6195684B2 (ja) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
MA45918A (fr) 2016-08-15 2019-06-19 Bayer Ag Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
USRE50663E1 (en) 2017-10-04 2025-11-18 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
KR20200131268A (ko) 2018-03-12 2020-11-23 바이엘 악티엔게젤샤프트 해충 방제제로서의 융합된 비시클릭 헤테로시클릭 유도체
AU2019254499A1 (en) 2018-04-20 2020-12-03 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
TWI724753B (zh) 2019-01-25 2021-04-11 大陸商北京賽特明強醫藥科技有限公司 醯胺基橋連雜環類化合物、及其組合物與應用
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法
WO2025094987A1 (ja) 2023-10-31 2025-05-08 日本農薬株式会社 スルホニル基を有する含窒素複素環化合物及び該化合物を含有する農園芸用除草剤並びにそれらの使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
WO1995003056A1 (en) 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
US5789440A (en) 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
DE69433705T2 (de) 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
SK283240B6 (sk) 1993-11-19 2003-04-01 Parke, Davis & Company 5,6-Dihydropyrónové deriváty ako inhibítory proteázy a protivírusové činidlá a farmaceutická kompozícia obsahujúca tieto deriváty
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
KR20010085780A (ko) 1998-09-11 2001-09-07 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Hiv 프로테아제 억제제
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
UA88909C2 (ru) * 2004-08-18 2009-12-10 Пфайзер Инк. Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение

Also Published As

Publication number Publication date
IL192919A0 (en) 2009-02-11
TWI376379B (en) 2012-11-11
MA28803B1 (fr) 2007-08-01
CR8935A (es) 2007-07-24
GT200500221A (es) 2006-06-21
TW200612898A (en) 2006-05-01
JP2008509984A (ja) 2008-04-03
EP1781662B1 (en) 2011-04-20
UY29068A1 (es) 2006-03-31
ATE506364T1 (de) 2011-05-15
CY1111480T1 (el) 2015-08-05
AU2005273619B2 (en) 2009-05-28
NI200700043A (es) 2008-01-02
IL180933A0 (en) 2007-07-04
US20090281122A1 (en) 2009-11-12
AU2005273619A1 (en) 2006-02-23
CN101006092A (zh) 2007-07-25
GEP20094751B (en) 2009-08-10
EP1781662A1 (en) 2007-05-09
KR20070044057A (ko) 2007-04-26
CA2577525C (en) 2010-03-30
PL1781662T3 (pl) 2011-08-31
US20060122399A1 (en) 2006-06-08
CN101006092B (zh) 2013-04-17
AP2007003918A0 (en) 2007-02-28
US20070015764A1 (en) 2007-01-18
ES2361845T3 (es) 2011-06-22
HRP20110458T1 (hr) 2011-07-31
ZA200700779B (en) 2008-11-26
HK1109617A1 (en) 2008-06-13
RS51794B (sr) 2011-12-31
DK1781662T3 (da) 2011-06-27
US8268835B2 (en) 2012-09-18
EA012605B1 (ru) 2009-10-30
SI1781662T1 (sl) 2011-07-29
KR100851178B1 (ko) 2008-08-08
WO2006018725A1 (en) 2006-02-23
DE602005027580D1 (de) 2011-06-01
NL1029755C2 (nl) 2006-10-18
SV2007002202A (es) 2007-03-20
PE20060677A1 (es) 2006-08-11
PT1781662E (pt) 2011-07-01
MX2007001527A (es) 2007-03-27
AP2313A (en) 2011-10-31
CN101538268B (zh) 2011-07-27
US7622605B2 (en) 2009-11-24
CR20110153A (es) 2011-04-26
NZ552874A (en) 2010-04-30
EA200700338A1 (ru) 2007-08-31
NO20071274L (no) 2007-05-14
CN101538268A (zh) 2009-09-23
MY146123A (en) 2012-06-29
JP4372195B2 (ja) 2009-11-25
HN2005000449A (es) 2009-10-30
NL1029755A1 (nl) 2006-02-21
AR050699A1 (es) 2006-11-15
ECSP077264A (es) 2007-04-26
CA2577525A1 (en) 2006-02-23
US7151105B2 (en) 2006-12-19
TNSN07066A1 (fr) 2008-06-02
GEP20115305B (en) 2011-10-10
UA88909C2 (ru) 2009-12-10
IL180933A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
BRPI0407699A (pt) Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
UY28084A1 (es) Derivados antivirales de nucleosidos
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BRPI0508217A (pt) cetamidas com p4's cìclico como inibidores de ns3 serina protease de vìrus de hepatite c
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
EA200901241A1 (ru) Соединения для лечения гепатита с
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BR0305259A (pt) Inibidores de hcv ns5b polimerase
EA200900297A1 (ru) Ингибиторы вируса гепатита с
ATE541844T1 (de) Antivirale verbindungen
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
ATE475660T1 (de) Antivirale verbindungen
BRPI0811633A2 (pt) compostos de fórmulas (i) e (ii), método de tratamento de hospedeiro infectado por hiv-1, hiv-2, hbv ou hcv, método de prevenção de infecção por hiv-1, hiv-2, hbv ou hcv, método para reduzir atividade biológica de infecção por hiv-1, hiv-2, hbv ou hcv e composição farmacêutica
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2317 DE 02-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.